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CancerAbstract Prompted by the literature report on anticancer properties of mefenamic acid, a series of
mefenamic acid based indole derivatives were designed via a rational approach. Synthesis of this
class of compounds was carried out via a 3-step method starting from the mefenamic acid and using
the Pd/C–Cu mediated coupling-cyclization strategy as a key step. A focused library of related
molecules was synthesized and evaluated for their anti-proliferative properties against normal
(HEK293T) and oral (CAL 27) as well as breast (MCF-7) cancer cell lines when several compounds
showed selective growth inhibition of oral cancer cells of which the compound 5g [i.e. N-(2-(((5-ﬂ
uoro-1-(methylsulfonyl)-1H-indol-2-yl)methoxy)methyl)phenyl)-2,3-dimethylaniline] was found to
be promising.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Among the various types of cancer, head and neck squamous
cell carcinoma (HNSCC) including oral squamous cell carci-
noma (OSCC) has emerged as the 6th most common malig-
nancy worldwide (Pentenero et al., 2005; Chen et al., 2004).
While reports suggest that more than 90% of oral cancerbelongs to OSCC class, the diagnosis of this disease is often
managed poorly (Funk et al., 2002; Muir and Weiland,
1995). For example, in spite of the availability of several treat-
ment options including surgery, radiation and multi-drug
chemotherapy, no signiﬁcant rise of long-term survival for
HNSCC patients has been observed in the recent past.
Additionally, the unwanted side effects associated with the
existing therapies and their unsatisfactory therapeutic actions
at the end stage of the disease underline the need of better
and new chemotherapeutic agents. Thus the discovery of novel
small molecules as potential antiproliferative/cytotoxic agents
not only is the essential need but also considered as an impor-
tant approach to target HNSCC. In spite of posing consider-
able challenges this approach attracted enormous attention
of medicinal/organic chemists.Journal
2 P. Vijaya Babu et al.Several studies have indicated that non-steroidal anti-
inﬂammatory drugs (NSAIDs) induce apoptosis in colon
(Hara et al., 1997; Richter et al., 2001; Thun et al., 1993,
1991), breast (Harris et al., 1996), prostate (Hsu et al., 2000),
and stomach (Sawaoka et al., 1998) cancer cells. For example,
mefenamic acid (A, Fig. 1), a well known member of NSAIDs
has been reported to show anti-proliferative effects as well as
apoptosis when tested against human liver cancer cell lines
(Woo et al., 2004). These reports prompted us to explore mefe-
namic acid as a potential starting point for the identiﬁcation of
new anti-proliferative agents. Due to the known anticancer
properties (Jacquemard et al., 2008; Prasad et al., 2010;
Tabata et al., 1993), 2-substituted indoles also attracted our
attention. For example, an indole based derivative that is 4-(5-
(1H-indol-2-yl)pyridin-3-yl)phenol has been identiﬁed as a
CDK inhibitor as well as cytotoxic agent (Jacquemard et al.,
2008) whereas indoles B (Fig. 1) containing a –CH2OCH– linker
at C-2 position have shown anticancer properties (Prasad et al.,
2010). Thus the integration of structural features of mefenamic
acidAand indole B in a singlemolecular entitymay afford a new
template C (Fig. 1) for the identiﬁcation of novel antiprolifera-
tive agents. Prompted by this idea and due to our interest in
novel anticancer agents we constructed a focused library of
small molecules based on C for in vitro screen. Herein, we report
the Pd/C-mediated direct synthesis ofmefenamic acid based sev-
eral novel indole analogues via a coupling-cyclization strategy
(Scheme 1) and their cytotoxic effects against oral cancer cells.
To the best of our knowledge any earlier efforts toward the syn-
thesis of this class of compounds and their pharmacological
evaluation is not known in the literature.
Due to their occurrences in nature and a wide range of
pharmacological properties, synthesis of indole has been a
topic of extensive research over the years (Humphrey and
Kuethe, 2006; Cacchi and Fabrizi, 2005; Gribble, 1996;
Tabata et al., 1993; Kru¨ger et al 2008; Ackermann 2007)
Among the various methods reported toward the synthesis of
2-substituted indoles, those catalyzed by transitional metals
have attracted particular attention. Not surprisingly, the palla-
dium catalyzed reactions occupied the center stage because of
their versatility, functional group tolerance and milder reac-
tion conditions. A broad range of Pd catalysts have been
employed for the synthesis of 2-substituted indoles. As a less
expensive catalyst system Pd/C-based catalyst for example
Pd/C–CuI–PPh3 has gained considerable interest for the efﬁ-
cient synthesis of various heterocyclic structures (Pal, 2009)
including indoles (Pal et al., 2004; Layek et al., 2009;
Alinakhi et al., 2011; Rao et al., 2011). The catalyst Pd/C is
stable and easy to handle as well as separable from the prod-
uct. Thus, we decided to explore this Pd/C based coupling–cy-
clization strategy leading to indoles for accessing our target
compounds based on C (Fig. 1). In order to expedite this strat-
egy we required to synthesize the appropriate starting material
that is the terminal alkyne necessary for our synthesisONH
MeMe
NH
A C
MeMe
O
OH
Figure 1 Design of mefenamic acid bas
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namic acid (1) was reduced in the presence of LiAlH4 to give
the corresponding alcohol (Babu et al., 2014) 2 which on treat-
ment with propargyl bromide in the presence of NaH afforded
the expected terminal alkyne 3 (Scheme 2).
2. Materials and methods
2.1. General
Unless stated otherwise, reactions were performed under nitro-
gen atmosphere. Reactions were monitored by thin layer chro-
matography (TLC) on silica gel plates (60 F254), visualizing
with ultraviolet light or iodine spray. Flash chromatography
was performed on silica gel (100–200 and 230–400 mesh) using
hexane, ethyl acetate, dichloromethane. 1H and 13CNMR spec-
tra were recorded either in CDCl3 or in DMSO-d6 solution by
using a Varian 400 MHz spectrometer. Proton chemical shifts
(d) are relative to tetramethylsilane (TMS, d= 0.00) as internal
standard and expressed in ppm. Spin multiplicities are given as s
(singlet), d (doublet), t (triplet) and m (multiplet) as well as b
(broad). Coupling constants (J) are given in hertz. Infrared spec-
tra were recorded on a JASCO FT-IR 4200 spectrometer.
Melting points were determined using a POLMON melting
point apparatus and are uncorrected.MS spectra were obtained
on an AGILENT-6430 LC-MS/MS-Quadruple spectrometer.
2.2. Preparation of (2-(2,3-
dimethylphenylamino)phenyl)methanol (2)
To a mixture of compound 1 (8.0 g, 33.1 mmol) in dry THF
(50 mL), was added lithium aluminum hydride (LAH) (2.0 g,
49 mmol) at 0 C under a nitrogen atmosphere and the reac-
tion mixture was stirred at room temperature for 2 h. After
completion of the reaction (indicated by TLC), the excess of
LAH was quenched by adding ice (2 g) portion wise. The mix-
ture was then extracted with ethyl acetate (3 · 15 mL), washed
with brine (10 mL), dried over anhydrous Na2SO4, ﬁltered and
concentrated under reduced pressure. The residue obtained
was puriﬁed by column chromatography on silica gel (230–
400 mesh) using 20% ethyl acetate/n-hexane to give desired
compound 2 (yield 92%); yellow liquid; 1H NMR (400 MHz,
CDCl3): d 7.21–7.17 (m, 2H), 7.11–7.04 (m, 2H), 6.99 (d,
J = 8.8 Hz, 1H), 6.89 (d, J = 6.8 Hz, 1H), 6.82 (t,
J = 7.6 Hz, 1H), 6.35 (s, 1H), 4.75 (s, 2H), 2.34 (s, 3H), 2.16
(s, 3H), 1.82 (s, 1H); MS (CI): 227.8 (M+ 1).
2.3. Preparation of 2,3-dimethyl-N-(2-((prop-2-
ynyloxy)methyl)phenyl)aniline (3)
Propargyl bromide (19.2 mmol) was added to a solution of (2-
(2,3-dimethylphenylamino)phenyl)methanol (16 mmol) andN N
O
Ar2
Ar1
B
ed novel anti cancer small molecules.
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Scheme 1 Pd/C-mediated synthesis of mefenamic acid based novel indole derivatives (C) via a coupling-cyclization strategy.
Me
Me HN
O
Me
Me
H
N
COOH
LAH
THF
rt, 2h
92%
Me
Me
H
N
OH
NaH
THF
rt, 7h
60%1 2 3
Br
Scheme 2 Synthesis of 2,3-dimethyl-N-(2-((prop-2-ynyloxy)methyl)phenyl)aniline (3).
Mefenamic acid based novel indole analogues 3sodium hydride (32 mmol) in THF (20 mL) under a nitrogen
atmosphere. The mixture was stirred at room temperature
for 7 h. After completion of the reaction (conﬁrmed by
TLC), the mixture was diluted with ice water (60 mL) and
extracted with ethyl acetate (3 · 15 mL). The organic layers
were collected, combined, dried over anhydrous Na2SO4, ﬁl-
tered and concentrated under low vacuum. The residue was
puriﬁed by column chromatography using hexane/ethyl acet-
ate as a eluent to afford the title compound as a liquid; yield:
60%, Liquid, Rf = 0.3 (40% EtOAc-n-Hexane); IR (KBr)
vmax: 3464, 2930, 1835, 2230 cm
1; 1H NMR (400 MHz,
CDCl3) d: 7.22 (ddd, J = 16.3, 11.7, 4.7 Hz, 2H), 7.14 (d,
J = 7.5 Hz, 1H), 7.07 (t, J = 7.6 Hz, 1H), 7.03–6.99 (m,
1H), 6.90 (d, J = 7.2 Hz, 1H), 6.82 (dt, J = 7.3, 1.08 Hz,
1H), 6.70 (s, 1H), 4.72 (s, 2H), 4.22 (d, J = 2.3 Hz, 2H), 2.50
(t, J = 2.3 Hz, 1H), 2.35 (s, 3H), 2.17 (s, 3H); 13C NMR
(100 MHz, CDCl3) d: 144.7, 140.4, 137.9, 130.8, 129.6, 128.0,
125.8, 124.3, 122.8, 118.9, 118.4, 115.3, 75.1, 71.5, 70.8, 56.9,
20.7, 13.5; MS (ES mass): m/z 266 (M+ 1, 100%).
2.4. General procedure for the preparation of compound (5)
A mixture of iodo compound 4 (1 equiv), 10% palladium car-
bon (0.016 equiv.), triphenylphosphine (0.125 equiv.), cuprous
iodide (0.02 equiv.) and triethylamine (2 equiv.) in methanol
(5 mL) was stirred for 30 min under nitrogen atmosphere. To
this mixture was added alkyne 3 (1 equiv) slowly and the mix-
ture was reﬂuxed for 4–8 h. After completion of the reaction
(indicated by TLC) the mixture was then cooled to room tem-
perature, ﬁltered through celite, and methanol was removed
under reduced pressure. The residue was diluted with water
(50 mL) and extracted with ethyl acetate (3 · 25 mL). The
organic layers were collected, combined, washed with water
(2 · 25 mL), dried over anhydrous sodium sulfate, ﬁltered
and concentrated. The residue thus obtained was puriﬁed by
column chromatography to afford the desired compound.
2.5. 2,3-Dimethyl-N-(2-(((1-(methylsulfonyl)-1H-indol-2-
yl)methoxy)methyl)phenyl)aniline (5a)
Yield: 65%; Brown liquid; Rf = 0.2 (40% EtOAc-n-Hexane);
IR (KBr) vmax: 3338, 2924, 1580, 1360 cm
1; 1H NMR
(400 MHz, CDCl3): d 8.05 (d, J = 8.3 Hz, 1H), 7.58 (d,Please cite this article in press as: Vijaya Babu, P. et al., Mefenamic acid based novel
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J = 7.5 Hz, 1H), 7.25–7.16 (m, 2H), 7.06 (td, J = 15.1,
7.4 Hz, 2H), 6.94 (d, J = 8.1 Hz, 1H), 6.89 (d, J = 6.9 Hz,
1H), 6.81 (t, J = 7.3 Hz, 1H), 6.69 (s, 1H), 6.64 (s, 1H), 4.85
(s, 2H), 4.73 (s, 2H), 3.15 (s, 3H), 2.30 (s, 3H), 2.06 (s, 3H);
13C NMR (100 MHz, CDCl3): d 144.9, 140.4, 137.9, 137.0,
136.2, 130.5, 129.4, 128.4 (2C), 125.9, 125.2, 124.5, 123.6,
123.4, 121.2, 118.9, 118.8, 115.3, 113.9, 111.7, 71.8, 64.4,
41.0, 20.7, 13.6; MS (CI): 435 (M+ 1, 100%); HPLC: 99%,
Column: Symmetry C-18 75 * 4.6 mm 3.5 lm, mobile phase
A: 0.1% TFA in water, mobile phase B: ACN (T/%B): 0/20,
0.5/20, 2/95, 8/95, 10/20, 12/20; ﬂow rate: 1.0 mL/min, UV
210 nm, retention time 5.2 min.
2.6. 2,3-Dimethyl-N-(2-(((1-tosyl-1H-indol-2-
yl)methoxy)methyl)phenyl)aniline (5b)
Yield: 70%; White solid; mp 110 C, Rf = 0.2 (35% EtOAc-n-
Hexane); IR (KBr) vmax: 3386, 2942, 1586, 1353 cm
1; 1H
NMR (400 MHz, CDCl3): d 8.17 (d, J = 8.3 Hz, 1H), 7.78
(d, J = 8.0 Hz, 2H), 7.52 (d, J = 7.3 Hz, 1H), 7.35 (t,
J = 7.5 Hz, 1H), 7.27–7.17 (m, 3H), 7.06 (d, J = 7.2 Hz,
4H), 6.99 (t, J = 10.8 Hz, 1H), 6.93–6.83 (m, 2H), 6.71 (d,
J = 10.7 Hz, 2H), 4.96 (s, 2H), 4.72 (s, 2H), 2.30 (s, 3H),
2.27 (s, 3H), 1.99 (s, 3H); 13C NMR (100 MHz, CDCl3):
144.9, 144.6, 140.6, 137.7, 137.0, 136.8, 135.7, 130.4, 129.5
(2C), 129.2, 128.8, 128.2, 126.7 (2C), 125.7, 124.8, 124.2,
123.6, 123.4, 120.9, 118.8, 118.6, 115.3, 114.5, 111.4, 71.8,
64.7, 21.4, 20.6, 13.5. MS (CI): 511.3 (M+ 1, 100%);
HPLC: 99.6%, Column: X-Terra C-18 250 * 4.6 mm, 5 lm,
mobile phase A: 5 mm Ammonium acetate in water, mobile
phase B: ACN (T/%B): 0/20, 3/20, 12/95, 23/95, 25/20,
30/20; ﬂow rate: 1.0 mL/min, Diluent: ACN: WATER
(50:50) UV 210 nm, retention time 15.7 min.
2.7. 2,3-Dimethyl-N-(2-(((5-methyl-1-(methylsulfonyl)-1H-
indol-2-yl)methoxy)methyl)phenyl) aniline (5c)
Yield: 65%; White Solid; mp 136 C, Rf = 0.35 (40% EtOAc-
n-Hexane); IR (KBr) vmax: 3379, 2925, 1587, 1357 cm
1; 1H
NMR (400 MHz, CDCl3): d 7.94 (d, J = 8.5 Hz, 1H), 7.38
(s, 1H), 7.22–7.18 (m, 3H), 7.09–7.05 (m, 2H), 6.95–6.93 (m,
2H), 6.83 (t, J = 7.2 Hz, 1H), 6.65-6.62 (m, 2H), 4.84 (s,indole analogues: Their synthesis and anti-proliferative eﬀects. Arabian Journal
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(s, 3H); 13C NMR (100 MHz, CDCl3): d 144.9, 140.5, 137.9,
136.2, 135.3, 133.2, 130.5, 129.4, 128.7, 128.4, 126.6, 125.9,
124.5, 123.4, 121.1, 118.9 (2C), 115.2, 113.6, 111.6, 71.8,
64.4, 40.8, 21.2, 20.7, 13.7; MS (CI): 449.1 (M+ 1, 100%);
HPLC: 99.5%, Column: Symmetry C-18 75 * 4.6 mm 3 lm,
mobile phase A: 0.1% TFA in water, mobile phase B: ACN
(T/%B): 0/50, 1/50, 3/98, 10/98, 10.5/50, 12/50; ﬂow rate:
1.0 mL/min, UV 260 nm, retention time 5.1 min.
2.8. 2,3-Dimethyl-N-(2-(((5-methyl-1-tosyl-1H-indol-2-
yl)methoxy)methyl)phenyl)aniline (5d)
Yield: 70%; Light yellow solid; mp 145 C, Rf = 0.4 (40%
EtOAc-n-Hexane); IR (KBr) vmax: 3338, 2927, 1580, 1370,
cm1; 1H NMR (400 MHz, CDCl3): d 8.01 (d, J = 8.5 Hz,
1H), 7.73 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 4.2 Hz, 1H),
7.25–7.10 (m, 3H), 7.06–6.97 (m, 4H), 6.95 (d, J = 8.0 Hz,
1H), 6.89–6.80 (m, 2H), 6.69 (s, 1H), 6.60 (s, 1H), 4.91 (s,
2H), 4.69 (s, 2H), 2.41 (s, 3H), 2.24 (s, 3H), 2.23 (s, 3H),1.97
(s, 3H); 13C NMR (100 MHz, CDCl3): d 145.0, 144.6, 140.6,
137.8, 136.8, 135.8, 135.3, 133.1, 130.5, 129.5 (2C), 129.2,
129.1, 128.3, 126.7 (2C), 126.2, 125.8, 124.2, 123.7, 120.8,
118.8, 118.7, 115.3, 114.2, 111.4, 71.8, 64.7, 21.4, 21.2, 20.6,
13.5; MS (CI): 525.2 (M+ 1, 100%); HPLC: 92.3%,
Column: X-Terra C-18 250 * 4.6 mm, 5 lm, mobile phase A:
5 mm Ammonium acetate in water, mobile phase B: ACN
(T/%B): 0/20, 3/20, 12/95, 23/95, 25/20, 30/20; ﬂow rate:
1.0 mL/min, Diluent: ACN: WATER (50:50) UV 210 nm,
retention time 15.9 min.
2.9. N-(2-(((5,7-Dimethyl-1-(methylsulfonyl)-1H-indol-2-
yl)methoxy)methyl)phenyl)-2,3-dimethylaniline (5e)
Yield: 68%; Semi solid; Rf = 0.4 (50% EtOAc-n-Hexane); IR
(KBr) vmax: 3391, 2926, 1610, 1473 cm
1; 1H NMR (400 MHz,
CDCl3): 7.19–7.15 (m, 3H), 7.08-7.01 (m, 2H), 6.97 (s, 1H),
6.97–6.86 (m, 2H), 6.79 (t, J = 7.3 Hz, 1H), 6.64 (d,
J = 10.6 Hz, 2H), 4.85 (s, 2H), 4.67 (s, 2H), 3.11 (s, 3H),
2.64 (s, 3H), 2.39 (s, 3H), 2.29 (s, 3H), 2.04 (s, 3H);13C
NMR (100 MHz, CDCl3): d 144.9, 140.4, 139.4, 137.8, 136.4,
134.0, 131.5, 130.5, 130.4, 129.3, 128.4, 126.1, 125.8, 124.4,
123.4, 118.9, 118.8 (2C), 115.2, 114.1, 71.6, 66.1, 40.7, 22.1,
20.8, 20.6, 13.5; MS (CI): 463.0 (M+ 1, 100%); HPLC:
97%, Column: Symmetry C-18 75 * 4.6 mm 3.5 lm, mobile
phase A: 0.1% TFA in water, mobile phase B: ACN
(T/%B): 0/50, 1/50, 3/98, 10/98, 10.5/50, 12/50; ﬂow rate:
1.0 mL/min, UV 260 nm, retention time 5.2 min.
2.10. N-(2-(((5,7-Dimethyl-1-tosyl-1H-indol-2-
yl)methoxy)methyl)phenyl)-2,3-dimethylaniline (5f)
Yield: 60%; Brown liquid; Rf = 0.35 (40% EtOAc-n-Hexane);
IR (KBr) vmax: 3380, 2927, 1796,, 1226 cm
1; 1H NMR
(400 MHz, CDCl3): d 7.38 (d, J = 8.3 Hz, 2H), 7.21–7.15 (m,
2H), 7.05–7.00 (m, 5H), 6.94–6.90 (m, 2H), 6.90–6.86 (m,
1H), 6.80 (dt, J = 7.3, 1.07 Hz, 1H), 6.66 (s, 1H), 6.60 (s,
1H), 4.88 (s, 2H), 4.69 (s, 2H), 2.57 (s, 3H), 2.35–2.32 (m,
3H), 2.29 (s, 3H), 2.28 (s, 3H), 2.02 (s, 3H); 13C NMR
(100 MHz, CDCl3): d 144.9 144.1, 140.6, 140.4, 137.7, 137.2,
135.1, 134.3, 132.6, 130.4, 130.3, 129.2 (2C), 128.4, 127.6,Please cite this article in press as: Vijaya Babu, P. et al., Mefenamic acid based novel
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114.2, 71.9, 66.3, 22.0, 21.5, 20.9, 20.6, 13.6; MS (CI): 539.1
(M+ 1, 100%); HPLC: 90%, Column: Symmetry C-18
75 * 4.6 mm 3.5 lm, mobile phase A: 0.1% TFA in water,
mobile phase B: ACN (T/%B): 0/20, 0.5/20, 2/95, 8/95,
10/20, 12/20; ﬂow rate: 1.0 mL/min, UV 210 nm, retention
time 5.7 min.
2.11. N-(2-(((5-Fluoro-1-(methylsulfonyl)-1H-indol-2-
yl)methoxy)methyl)phenyl)-2,3-dimethylaniline (5g)
Yield: 68%; Light yellow solid; mp 110–112 C; Rf = 0.3
(45% EtOAc-n-Hexane); IR (KBr) vmax: 3382, 2930, 1592,
1363 cm1; 1H NMR (400 MHz, CDCl3): d 8.00 (dd,
J = 9.1, 4.3 Hz, 1H), 7.25–7.17 (m, 3H), 7.08–7.05 (m, 3H),
6.97–6.88 (m, 2H), 6.82–6.79 (m, 1H), 6.65 (s, 1H), 6.58 (s,
1H), 4.83 (s, 2H), 4.74 (s, 2H), 3.14 (s, 3H), 2.31 (s, 3H),
2.07 (s, 3H); 13C NMR (100 MHz, CDCl3): d 160.8 (d, C–F
J= 239.1), 144.8, 140.4, 137.8 (d, C–F J= 8.2), 133.3,
130.5, 129.5, 129.4 (d, C–F J= 10.1), 128.3, 125.8, 124.5,
123.2, 118.9, 118.8, 115.3 (d, C–F J= 9.0), 113.2 (d, C–F
J= 25.2), 111.3, 111.2, 109.9, 106.7 (d, C–F J= 23.8), 71.9,
64.3, 41.1, 20.7, 13.6; MS (CI): 453 (M+ 1, 100%); HPLC:
97.7%, Column: Symmetry C-18 75 * 4.6 mm 3.5 lm, mobile
phase A: 0.1% TFA in water, mobile phase B: ACN
(T/%B): 0/20, 1/20, 6/98, 10/98, 12/20, 15/20; ﬂow rate:
1.0 mL/min, UV 210 nm, retention time 7.8 min.
2.12. N-(2-(((5-Fluoro-1-tosyl-1H-indol-2-
yl)methoxy)methyl)phenyl)-2,3-dimethylaniline (5h)
Yield: 70%; White solid; mp 104–106 C; Rf = 0.4 (40%
EtOAc-n-Hexane); IR (KBr) vmax: 3387, 2948, 1596, 1353,
1262 cm1; 1H NMR (400 MHz, CDCl3): d 8.08 (dd,
J = 9.1, 4.4 Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.23–7.16 (m,
2H), 7.13 (dd, J = 8.5, 2.5 Hz, 1H), 7.09–6.98 (m, 5H), 6.94
(d, J = 7.9 Hz, 1H), 6.85–6.87 (m, 2H), 6.63 (d, J = 4.5 Hz,
2H), 4.91 (s, 2H), 4.70 (s, 2H), 2.27 (s, 3H), 2.28 (s, 3H),
1.95 (s, 3H); 13C NMR (100 MHz, CDCl3): d 160.8 (d, C–F
J= 239.0), 144.9 (2c), 140.5, 138.6 (d, C–F J= 86.7), 135.5,
130.5, 129.9 (d, C–F J= 10.0) 129.6 (2C), 129.3, 128.3,
126.7 (2C), 125.8, 124.3, 123.5, 118.8, 118.7, 115.6 (d, C–F
J= 9.2), 115.3, 112.8 (d, C–F J= 30.0), 112.5, 111.0 (2C),
106.5 (d, C–F J= 23.7), 71.9, 64.7, 21.4, 20.6, 13.5; MS
(CI): 528.2 (M+ 1, 100%); HPLC: 99.6%, Column: X-
Terra C-18 250 * 4 mm, 5 lm, mobile phase A: 5 mm
Ammonium acetate in water, mobile phase B: ACN (T/%B):
0/20, 3/20, 6/98, 12/95, 23/95, 25/20, 30/20; ﬂow rate:
1.0 mL/min, Diluent: ACN: WATER (50:50) UV 210 nm,
retention time 16.0 min.
2.13. N-(2-(((5-Chloro-1-(methylsulfonyl)-1H-indol-2-
yl)methoxy)methyl)phenyl)-2,3-dimethylaniline (5i)
Yield: 65%; Light green solid; mp 110 C, Rf = 0.25 (40%
EtOAc-n-Hexane); IR (KBr) vmax: 3369, 2931, 1594,
1375 cm1; 1H NMR (400 MHz, CDCl3): d 7.97 (d,
J = 8.9 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.37–7.27 (m,
3H), 7.26–7.16 (m, 2H), 6.95–6.90 (m, 2H), 6.82 (t,
J = 7.3 Hz, 1H), 6.63 (s, 1H), 6.57 (s, 1H), 4.82 (s, 2H), 4.73
(s, 2H), 3.15 (s, 3H), 2.30 (s, 3H), 2.06 (s, 3H); 13C NMRindole analogues: Their synthesis and anti-proliferative eﬀects. Arabian Journal
Table 1 Effect of reaction conditions on coupling of terminal alkyne 3 with 4ja.
Entry Pd-catalyst Base Time Yieldb
1. 10% Pd/C-PPh3 Et3N 5 70
2. 10% Pd/C-PPh3 Et3N 7 80
3. 10% Pd/C-PPh3 Et3N 9 65
4. Pd(OAc)2 Et3N 7 42
5. PPh3 Et3N 7 17
6. No catalyst Et3N 2 No reaction
7. 10% Pd/C-PPh3 K2CO3 7 46
a All reactions were carried out using alkyne 3 (1 equiv.), 4j (1 equiv.), a Pd-catalyst (0.016 equiv.), PPh3 (0.125 equiv.), CuI (0.02 equiv.), and
Et3N (2 equiv.) in MeOH (5.0 mL) at 65 C.
b Isolated yields.
Mefenamic acid based novel indole analogues 5(100 MHz, CDCl3): d 144.8, 140.4, 137.9, 137.6, 135.3, 133.8,
130.5, 129.5, 129.3, 128.6, 125.9, 125.3, 124.5, 123.2, 120.7,
118.9, 118.8, 115.3, 115.0, 110.7, 72.0, 64.3, 41.2, 20.7, 13.6;
MS (CI): 469.1 (M+, 100%), 571.2 (M+ 2, 33%); HPLC:
97.5%, Column: Symmetry C-18 75 * 4.6 mm 3.5 lm, mobile
phase A: 0.1% TFA in water, mobile phase B: ACN
(T/%B): 0/20, 0.5/20, 2/95, 8/95, 10/20, 12/20; ﬂow rate:
1.0 mL/min, UV 210 nm, retention time 5.8 min.
2.14. N-(2-(((5-Chloro-1-tosyl-1H-indol-2-
yl)methoxy)methyl)phenyl)-2,3-dimethylaniline (5j)
Yield: 80%; White solid; Rf = 0.35 (35% EtOAc-n-Hexane);
IR (KBr) vmax: 3309, 2943, 1603, 1370 cm
1; 1H NMR
(400 MHz, CDCl3): d 8.09 (d, J = 8.9 Hz, 1H), 7.73 (d,
J = 8.3 Hz, 2H), 7.48 (d, J = 1.9 Hz, 1H), 7.30 (dd, J = 9.3,
2.50 Hz, 1H), 7.22 (dd, J = 13.0, 6.9 Hz, 2H), 7.05 (td,
J = 7.7, 6.7 Hz, 4H), 6.97 (d, J = 7.9 Hz, 1H), 6.92–6.82 (m,
2H), 6.64 (s, 2H), 4.93 (s, 2H), 4.72 (s, 2H), 2.30 (s, 3H),
2.28 (s, 3H), 1.97 (s, 3H); 13C NMR (100 MHz, CDCl3): d
145.0, 144.9, 140.5, 138.4, 137.8, 135.4, 135.3, 130.5, 130.1,
129.6 (2C), 129.3, 129.2, 128.2, 126.7 (2C), 125.8, 124.9,
124.3, 123.5, 120.4, 118.8, 118.7, 115.5, 115.3, 110.4, 72.0,
64.6, 21.4, 20.6, 13.5; MS (CI): 545.1 (M+, 100%), 547.2
(M+ 2, 32%); HPLC: 99.5%, Column: X-Terra C-18
250 * 4.6 mm, 5 lm, mobile phase A: 5 mm Ammonium acet-
ate in water, mobile phase B: ACN (T/%B): 0/20, 3/20,
12/95, 23/95, 25/20, 30/20; ﬂow rate: 1.0 mL/min, Diluent:
ACN: WATER (50:50) UV 210 nm, retention time 16.1 min.
2.15. N-(2-(((5-Bromo-1-(methylsulfonyl)-1H-indol-2-
yl)methoxy)methyl)phenyl)-2,3-dimethylaniline (5k)
Yield: 75%; White solid; mp 140 C, Rf = 0.32 (30% EtOAc-
n-Hexane); IR (KBr) vmax: 3379, 2927, 1587, 1356, 1322 cm
1;
1H NMR (400 MHz, CDCl3): d 7.93 (d, J = 8.8 Hz, 1H), 7.72
(d, J = 1.9 Hz, 1H), 7.45 (dd, J = 8.9, 1.90 Hz, 1H), 7.23–7.17
(m, 2H), 7.11–7.02 (m, 2H), 6.97–6.88 (m, 2H), 6.82 (t,
J = 7.3 Hz, 1H), 6.63 (s, 1H), 6.56 (s, 1H), 4.83 (s, 2H), 4.74
(s, 2H), 3.15 (s, 3H), 2.31 (s, 3H), 2.07 (s, 3H); 13C NMRPlease cite this article in press as: Vijaya Babu, P. et al., Mefenamic acid based novel
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.05.018(100 MHz, CDCl3): d 144.8, 140.4, 137.9, 137.5, 135.7, 130.5,
130.1, 129.5, 128.3, 128.0, 125.9, 124.6, 123.8, 123.2, 119.0,
118.9, 116.9, 115.4 (2C), 110.6, 72.0, 64.2, 41.2, 20.6, 13.6;
MS (CI): 513.1 (M+, 100%), 515.2 (M+ 2, 95%); HPLC:
99.3%, Column: X-Terra C-18 250 * 4.6 mm, 5 lm, mobile
phase A: 5 mm Ammonium acetate in water, mobile phase
B: ACN (T/%B): 0/20, 3/20, 12/95, 23/95, 25/20, 30/20; ﬂow
rate: 1.0 mL/min, Diluent: ACN: WATER (50:50) UV
230 nm, retention time 15.7 min.
2.16. N-(2-(((5-Bromo-1-tosyl-1H-indol-2-
yl)methoxy)methyl)phenyl)-2,3-dimethylaniline (5l)
Yield: 70%; White solid; mp 148 C, Rf = 0.45 (40% EtOAc-
n-Hexane); IR (KBr) vmax: 3387, 2927, 1594, 1354 cm
1; 1H
NMR (400 MHz, CDCl3): 8.01 (d, J = 8.8 Hz, 1H), 7.70 (d,
J = 8.3 Hz, 2H), 7.61 (d, J = 1.7 Hz, 1H), 7.41 (dd, J = 8.9,
1.9 Hz, 1H), 7.19 (dd, J = 13.5, 7.2 Hz, 2H), 7.10–6.98 (m,
4H), 6.94 (d, J = 8.1 Hz, 1H), 6.90–6.79 (m, 2H), 6.61 (s,
2H), 4.90 (s, 2H), 4.69 (s, 2H), 2.28 (s, 3H), 2.26 (s, 3H),
1.94 (s, 3H); 13C NMR (100 MHz, CDCl3): d 145.0, 144.9,
140.5, 138.2, 137.8, 135.7, 135.4, 130.6, 130.5, 129.6 (2C),
129.3, 128.2, 127.6, 126.7 (2C), 125.8, 124.3, 123.5 (2C),
118.8, 118.6, 116.8, 115.9, 115.3, 110.2, 72.0, 64.5, 21.4, 20.6,
13.5; MS (CI): 588.1 (M+, 100%), 590.2 (M+ 2, 95%);
HPLC: 99.4%, Column: X-Terra C-18 250 * 4.6 mm, 5 lm,
mobile phase A: 5 mm Ammonium acetate in water, mobile
phase B: ACN (T/%B): 0/20, 3/20, 12/95, 23/95, 25/20,
30/20; ﬂow rate: 1.0 mL/min, Diluent: ACN: WATER
(50:50) UV 210 nm, retention time 16.8 min.
2.17. Cell proliferation assay
The anti-proliferative activity and cancer cell selectivity of the
synthesized compounds on normal and cancer cells were eval-
uated using the SRB (Sulforhodamine B) cell proliferation
assay.
In brief, the assay was performed as follows: Cal 27 (oral
cancer cell line), MCF-7 (breast cancer cell line) and non-
cancer [Human Embryonic Kidney (HEK) 293T cell line] cellsindole analogues: Their synthesis and anti-proliferative eﬀects. Arabian Journal
Table 2 Synthesis of mefenamic acid based indole derivatives (5)a.
Entry o-Iodoanilide (4) Productsb (5) Time (h) Yieldc (%)
1 5 65
2 4.5 70
3 4 65
4 5 70
5 6 68
6 P. Vijaya Babu et al.
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Table 2 (continued)
Entry o-Iodoanilide (4) Productsb (5) Time (h) Yieldc (%)
6 6 60
7 6.5 68
8 7 70
9 8 65
10 7 80
(continued on next page)
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Table 2 (continued)
Entry o-Iodoanilide (4) Productsb (5) Time (h) Yieldc (%)
11 6 75
12 6.5 70
a All the reactions were carried out using alkyne 3 (1 equiv.), 4 (1 equiv.), 10% Pd/C (0.016 equiv.), PPh3 (0.125 equiv.), CuI (0.02 equiv.), and
Et3N (2 equiv.) in MeOH at 65 C.
b Identiﬁed by 1H and 13C NMR, IR, and MS.
c Isolated yields.
8 P. Vijaya Babu et al.were seeded in 96-well plates and incubated overnight. The
optimum cell numbers to be seeded were determined by a
growth curve analysis for each cell line. In the initial (single
dose) screen, compounds (dissolved in 100% DMSO to a stock
concentration of 100 mM) were added to the adhered cells at a
ﬁnal concentration of 10 lM. After 72 h of treatment, the cells
were washed with phosphate-buffered saline and ice-cold 10%
trichloroacetic acid was added to the cells to precipitate all
proteins for 1 h at 4 C. The cells were then washed with water
and air-dried. Cellular proteins were then stained using 0.4%
SRB solution in 1% acetic acid for 10 min at room tempera-
ture. The unbound dye was washed away by destaining with
1% acetic acid and bound dye solubilized with 10 lM Tris
solution. Absorbance of solubilized dye was measured at a
wavelength of 590 nm. Percentage growth was determined by
the formula [(At–A0/Ac–A0)] X 100, where At = absorbance
after 72 h of test compound treatment, A0 = Absorbance at
time 0, Ac = Absorbance after 72 h without treatment.
3. Results and discussion
3.1. Chemistry
In order to establish the optimized reaction conditions, the
Pd/C-mediated coupling of 3 with N-(4-chloro-2-iodophe
nyl)-4-methylbenzenesulfonamide (4j) was used as a model
reaction (Table 1). Initially, this reaction was carried out in
the presence of 10% Pd/C–PPh3–CuI and Et3N in MeOH at
reﬂuxing temperature (65 C) for 5 h when the expectedPlease cite this article in press as: Vijaya Babu, P. et al., Mefenamic acid based novel
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.05.018product 5j was isolated in 70% yield (Table 1, entry 1). An
increase of reaction time to 7 h however afforded 5j in 80%
yield (Table 1, entry 2). A further increase in reaction time
to 9 h did not improve the product yield (Table 1, entry 3).
In fact the yield was decreased in this case due to the partial
decomposition of the product perhaps due to its prolonged
exposure to Et3N/MeOH under the reﬂuxing conditions. The
use of other catalyst, for example Pd(OAc)2 afforded the pro-
duct 5j but in inferior yield under the conditions employed
(Table 1, entry 4). The omission of Pd/C (Table 1, entry 5)
was found to be less effective whereas the reaction did not pro-
ceed in the absence of 10% Pd/C–PPh3–CuI catalyst system
(entry 6, Table 1). While all these reactions were carried out
using Et3N as a base the use of an inorganic base for example
K2CO3 was also examined. The reaction proceeded in this case
affording the desired product 5j but the yield was only 46%
(Table 1, entry 7). Thus, 10% Pd/C–PPh3–CuI in combination
with Et3N in MeOH was found to be optimal (Table 1, entry 2)
and used to prepare other analogues of 5j. A number of o-
iodosulphanilides (4a–l) were reacted with the alkyne 3 under
the optimized conditions (Table 2). The reactions proceeded
well irrespective of the presence of groups such as Me, F, Cl,
and Br on the anilide ring affording the desired indoles 5 in
acceptable yields. All the indole derivatives (5) synthesized
were characterized by spectral (NMR, IR and MS) data. The
presence of indole ring was conﬁrmed by the appearance of
a singlet at 6.6 d due to the C-3 indole proton in the 1H
NMR spectra of 5. The two singlets near 4.9 and 4.7 d indi-
cated the presence of –CH2–O–CH2– moiety.indole analogues: Their synthesis and anti-proliferative eﬀects. Arabian Journal
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Scheme 3 Proposed reaction mechanism for the Pd/C–Cu mediated synthesis of 5 via the coupling-cyclization strategy.
Table 3 The % of growth inhibition of cancer cells by compound 5 at 10 lM.
Compounds (5) % inhibitiona
CAL 27 (oral cancer) MCF-7 (breast cancer) HEK 293T
5a; R =Me, Z = H 2.78 ± 1.40 10.21 ± 1.03 9.21 ± 2.79
5c; R =Me, Z =Me 28.70 ± 5.11 31.96 ± 3.22 4.65 ± 0.91
5g; R =Me, Z = F 55.56 ± 6.05 2.67 ± 1.31 8.10 ± 1.12
5h; R = C6H4Me-p, Z = F 47.22 ± 4.98 2.71 ± 0.97 0.89 ± 0.56
5i; R =Me, Z = Cl 25.92 ± 5.23 10.63 ± 2.05 0.24 ± 0.12
5k; R =Me, Z = Br 12.99 ± 1.76 9.66 ± 1.56 9.66 ± 2.11
5l; R = C6H4Me-p, Z = Br 44.45 ± 6.53 0.75 ± 0.25 0.39 ± 0.09
Gemcitabine 78 ± 2.05 59.17 ± 1.21 22.70 ± 1.45
a Average of at least three determinations.
Mefenamic acid based novel indole analogues 9A proposed reaction mechanism for the present Pd/C-
mediated synthesis of mefenamic acid based indole derivatives
(5) is shown in Scheme 3. The reaction seemed to proceed via
generation of an active Pd(0) species from Pd/C that actually
catalyze the C–C bond forming reaction between 3 and 4.
Thus, the active Pd(0) species generated in situ (Prasad et al.,
2012; Chen et al., 2007; Rambabu et al., 2013) (Scheme 3)
undergoes oxidative addition with 4 to give E-1. The organo-
Pd(II) species E-1 then undergoes trans organometallation
with copper acetylide generated in situ from CuI and 3 to
afford E-2. Notably, CuI is regenerated during this step. The
reductive elimination of Pd(0) from E-2 completes the Pd-
catalytic cycle and affords the internal alkyne E-3. In the next
step E-3 undergoes Cu-mediated intramolecular cyclization to
give the desired product 5 via E-4 with the regeneration of CuI.Please cite this article in press as: Vijaya Babu, P. et al., Mefenamic acid based novel
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.05.018Overall, the whole process seemed to proceed via two catalytic
cycles that is the Pd-cycle followed by a Cu-cycle.
3.2. Pharmacology
All the mefenamic acid based indole derivatives (5) synthesized
were tested for their anti-proliferative properties and cancer cell
selectivity against normal (Human Embryonic Kidney 293T or
HEK293T) and oral (oral adenosquamous or CAL27) aswell as
breast (MCF-7) cancer cell lines at 10 lM using a sulforho-
damine B (SRB) assay. This assay was chosen because of its sen-
sitivity, large dynamic range and the ability to measure cell
proliferation over three days with normalization to initial cell
number as well as vehicle-treated cells. Further, this is the assay
of choice for anticancer compound screening at the Nationalindole analogues: Their synthesis and anti-proliferative eﬀects. Arabian Journal
10 P. Vijaya Babu et al.Cancer Institute (NIH). The SRB assay provides a colorimetric
readout which can be spectrophotometrically measured and
does not involve the use of antibodies or toxic reagents. The
assay is based on detection of total protein content of cells,
which increases or decreases in proportion with cell number.
Gemcitabine was used as a reference compound in this assay
(Chu and DeVita, 2007). The results of representative com-
pounds found to be active along with few less or not active com-
pounds are presented in Table 3. The compounds 5g, 5h and 5l
were found to be active against oral cancer cells (Table 3)
whereas the compound 5c showed growth inhibition of breast
cancer cells (Table 3). It is evident from this study that a ﬂuorine
substituent at the C-5 position of indole ring is beneﬁcial (5g and
5h vs rest of the compounds except 5l) whereas a methanesul-
fonyl group at indole nitrogen is favored for growth inhibition
against CAL27 cells (compound 5g vs 5h). However, the p-
toluenesulfonyl group appeared to impart better selectivity than
the methanesulfonyl group (compound 5h and 5l vs rest of the
compounds). Notably, none of these compounds showed signif-
icant effect onHEK293T cells (Table 3) indicating their selectiv-
ity toward cancer cells especially oral cancer. While the exact
reason for such observation is not clear at this stage, this kind
of behavior of small organicmolecules has been reported by sev-
eral researchers in the literature earlier (Cui et al., 2015).
Nevertheless, though 5h and 5l showed better selectivity, the
compound 5g was identiﬁed as the best anti-proliferative agent
(55% growth inhibition) among the compounds tested against
oral cancer and therefore may be of further medicinal interest.
4. Conclusion
In conclusion, the concept of using mefenamic acid as a start-
ing point for the identiﬁcation of novel anti-proliferative
agents has been explored in the present study. Thus a series
of mefenamic acid based indole derivatives were designed via
a rational approach. Their design was prompted by the litera-
ture report on anticancer properties of mefenamic acid.
Synthesis of this class of compounds was carried out via a 3-
step method starting from the mefenamic acid. The Pd/C–Cu
mediated coupling-cyclization strategy leading to the construc-
tion of an indole ring was used as a key step when the desired
mefenamic acid based indole derivatives were isolated in
acceptable yields. A focused library of related molecules was
synthesized and evaluated for their anti-proliferative proper-
ties against normal (HEK293T) and oral (CAL 27) as well as
breast (MCF-7) cancer cell lines at 10 lM using a sulforho-
damine B (SRB) assay. Several of these compounds showed
selective growth inhibition of oral cancer cells of which the
compound 5g was found to be promising in terms of % growth
inhibition and may be of further interest. In summary, our
study indicated that the mefenamic acid based indole frame-
work presented here could be an attractive template for the
design of small molecules of potential pharmacological interest
that could be accessed conveniently via a Pd/C–Cu catalyzed
coupling-cyclization method.
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